Human Rabies Vaccine Market by Products (Pre-Exposure Vaccination and Post-Exposure Prophylaxis) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021-2028
The global human rabies market size is projected to register a substantial CAGR during the forecast period, 2021-2028 attributed to the increasing number of pets, pets having a low immunization rate, and increasing friendliness of the public with pets. Moreover, the rising geriatric population base having low immunity is also expected to drive market growth.
A virus that is deadly and which spreads to people from the saliva of infected animals is known as rabies. It usually happens when an individual is bitten or scratched by an animal, for instance, stray dogs. The common symptoms of rabies include excess salivation, headache, mental confusion, fever, paralysis, and muscle spasms. The other symptoms of rabies also include difficulty in respiration and hydrophobia. There is no specific treatment available for rabies; however, the infection can be prevented by using a vaccine. The symptoms of rabies may occur delay and could cause deadly effects. Therefore, the person who is bitten by an animal should be taken to the hospital or clinics immediately to administer human rabies vaccine. As per the reports by the World Health Organization (WHO), in 2015 about 99% of rabies cases were reported due to domestic dogs bite. Other animals whose scratch or contact of saliva causes rabies include cats, raccoons, bats, skunks, and foxes. More than 40% of people suffering from rabies are children under the age of 15. In the US, the most number of deaths due to rabies was caused by bats.
The COVID-19 pandemic outbreak had resulted a positive impact on the market. The reports by the Centers for Disease Control and Prevention (CDC) in 2020 suggested that animals such as dogs, cats, and others were at a great risk to be affected by SARS-CoV-2. Several studies are also been taken to understand the correlation of transmission of this deadly infection between humans and animals. A study published by the Nature magazine in October 2020 stated that a highly efficient, novel, and safe vaccine for COVID-19 could be developed using a rabies virus-based vector.
Market Trends, Drivers, Restraints, and Opportunities
- Globally, rise in the number of deaths caused due to rabies is anticipated to fuel the market growth during the forecast period.
- Presence of a large population of stray dogs and issues increasing related to them in low & middle-income countries are expected to propel the market growth.
- Increasing services for pet management and technological advancement are anticipated to drive the market expansion in the coming years.
- Absence of awareness in public and negligence showed by them are key challenges that can restrain the market growth over the forecast period.
- Increasing government initiatives and wide introduction or development of human rabies vaccines are projected to create lucrative opportunities for market growth.
Scope of the Report
The report on the global human rabies vaccine market includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.
| Attributes | Details |
| Report Title | Human Rabies Vaccine Market – Global Industry Analysis, Growth, Share, Size, Trends, And Forecast |
| Base Year | 2020 |
| Historic Data | 2018–2019 |
| Forecast Period | 2021–2028 |
| Segmentation | Products (Pre-Exposure Vaccination and Post-Exposure Prophylaxis) |
| Regional Scope | Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
| Report Coverage | Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
| Key Players Covered in the Report | Medimmune LLC.; Novartis Vaccines and Diagnostics Ltd.; GlaxoSmithKline Biologicals; Cadila Pharmaceuticals Ltd.; Merck & Co Inc.; Berna Biotech Ltd.; Sanofi Pasteur, Inc.; and Wyeth pharmaceuticals |
Market Segment Insights
Post-Exposure prophylaxis segment is expected to grow at a significant rate
On the basis of products, the global human rabies market is bifurcated into pre-exposure vaccination and post-exposure prophylaxis. The pre-exposure vaccination segment is projected to hold a key market share during the forecast period as it is widely given to individuals who are most likely to get infected by rabies such as wildlife officers, veterinarians, and people traveling to countries that have increased risk of rabies infection. However, the post-exposure prophylaxis segment is expected to grow at a significant rate in the coming years as it is given to an individual when they are bitten by an animal that is suspected to be rabid.
North America is anticipated to dominate the market
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during the projected period attributed to the presence of healthcare infrastructure that is well established, high awareness among healthcare professionals, and increasing initiatives by the government towards awareness of rabies. North America is followed by Europe with a very thin difference. The driving factors of the market in Europe are the presence of primary manufacturers in the region and increasing research & development activities for the development of vaccines that are more efficient. On the other hand, the market in Asia Pacific is estimated to expand at a rapid pace in the coming years owing to the presence of the wide number of domesticated animal population in the region.
Segments
Segments Covered in the ReportThe global human rabies vaccine market has been segmented on the basis of
Products
- Pre-Exposure Vaccination
- Post-Exposure Prophylaxis
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Medimmune LLC.
- Novartis Vaccines and Diagnostics Ltd.
- GlaxoSmithKline Biologicals
- Cadila Pharmaceuticals Ltd.
- Merck & Co Inc.
- Berna Biotech Ltd.
- Sanofi Pasteur, Inc.
- Wyeth pharmaceuticals
Competitive Landscape
Key players competing in the global human rabies vaccine market are Medimmune LLC.; Novartis Vaccines and Diagnostics Ltd.; GlaxoSmithKline Biologicals; Cadila Pharmaceuticals Ltd.; Merck & Co Inc.; Berna Biotech Ltd.; Sanofi Pasteur, Inc.; and Wyeth pharmaceuticals. Many of these players have adopted business strategies such as the launch of new products, the advancement of technologies, mergers, partnerships, and production capacity expansion to increase their market position and expand their consumer base globally.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Human Rabies Vaccine Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Human Rabies Vaccine Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Human Rabies Vaccine Market - Supply Chain
4.5. Global Human Rabies Vaccine Market Forecast
4.5.1. Human Rabies Vaccine Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Human Rabies Vaccine Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Human Rabies Vaccine Market Absolute $ Opportunity
5. Global Human Rabies Vaccine Market Analysis and Forecast by Region
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Region
5.2.2. Y-o-Y Growth Projections by Region
5.3. Human Rabies Vaccine Market Size and Volume Forecast by Region
5.3.1. North America
5.3.2. Latin America
5.3.3. Europe
5.3.4. Asia Pacific
5.3.5. Middle East and Africa (MEA)
5.4. Absolute $ Opportunity Assessment by Region
5.5. Market Attractiveness/Growth Potential Analysis by Region
5.6. Global Human Rabies Vaccine Demand Share Forecast, 2019-2026
6. North America Human Rabies Vaccine Market Analysis and Forecast
6.1. Introduction
6.1.1. Basis Point Share (BPS) Analysis by Country
6.1.2. Y-o-Y Growth Projections by Country
6.2. North America Human Rabies Vaccine Market Size and Volume Forecast by Country
6.2.1. U.S.
6.2.2. Canada
6.3. Absolute $ Opportunity Assessment by Country
6.4. Market Attractiveness/Growth Potential Analysis
6.4.1. By Country
6.4.2. By Product Type
6.4.3. By Application
6.5. North America Human Rabies Vaccine Demand Share Forecast, 2019-2026
7. Latin America Human Rabies Vaccine Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.1.3. Latin America Average Pricing Analysis
7.2. Latin America Human Rabies Vaccine Market Size and Volume Forecast by Country
7.2.1. Brazil
7.2.2. Mexico
7.2.3. Rest of Latin America
7.3. Absolute $ Opportunity Assessment by Country
7.4. Market Attractiveness/Growth Potential Analysis
7.4.1. By Country
7.4.2. By Product Type
7.4.3. By Application
7.5. Latin America Human Rabies Vaccine Demand Share Forecast, 2019-2026
8. Europe Human Rabies Vaccine Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Europe Average Pricing Analysis
8.2. Europe Human Rabies Vaccine Market Size and Volume Forecast by Country
8.2.1. Germany
8.2.2. France
8.2.3. Italy
8.2.4. U.K.
8.2.5. Spain
8.2.6. Russia
8.2.7. Rest of Europe
8.3. Absolute $ Opportunity Assessment by Country
8.4. Market Attractiveness/Growth Potential Analysis
8.4.1. By Country
8.4.2. By Product Type
8.4.3. By Application
8.5. Europe Human Rabies Vaccine Demand Share Forecast, 2019-2026
9. Asia Pacific Human Rabies Vaccine Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Asia Pacific Average Pricing Analysis
9.2. Asia Pacific Human Rabies Vaccine Market Size and Volume Forecast by Country
9.2.1. China
9.2.2. Japan
9.2.3. South Korea
9.2.4. India
9.2.5. Australia
9.2.6. Rest of Asia Pacific (APAC)
9.3. Absolute $ Opportunity Assessment by Country
9.4. Market Attractiveness/Growth Potential Analysis
9.4.1. By Country
9.4.2. By Product Type
9.4.3. By Application
9.5. Asia Pacific Human Rabies Vaccine Demand Share Forecast, 2019-2026
10. Middle East & Africa Human Rabies Vaccine Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Middle East & Africa Average Pricing Analysis
10.2. Middle East & Africa Human Rabies Vaccine Market Size and Volume Forecast by Country
10.2.1. Saudi Arabia
10.2.2. South Africa
10.2.3. UAE
10.2.4. Rest of Middle East & Africa (MEA)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Market Attractiveness/Growth Potential Analysis
10.4.1. By Country
10.4.2. By Product Type
10.4.3. By Application
10.5. Middle East & Africa Human Rabies Vaccine Demand Share Forecast, 2019-2026
11. Competition Landscape
11.1. Global Human Rabies Vaccine Market: Market Share Analysis
11.2. Human Rabies Vaccine Distributors and Customers
11.3. Human Rabies Vaccine Market: Competitive Dashboard
11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
11.4.1. Medimmune LLC. Novartis Vaccines and Diagnostics Ltd. GlaxoSmithKline Biologicals Cadila Pharmaceuticals Ltd. Merck & Co Inc. Berna Biotech Ltd.
2. Assumptions and Acronyms Used
3. Research Methodology
4. Human Rabies Vaccine Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Human Rabies Vaccine Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Human Rabies Vaccine Market - Supply Chain
4.5. Global Human Rabies Vaccine Market Forecast
4.5.1. Human Rabies Vaccine Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Human Rabies Vaccine Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Human Rabies Vaccine Market Absolute $ Opportunity
5. Global Human Rabies Vaccine Market Analysis and Forecast by Region
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Region
5.2.2. Y-o-Y Growth Projections by Region
5.3. Human Rabies Vaccine Market Size and Volume Forecast by Region
5.3.1. North America
5.3.2. Latin America
5.3.3. Europe
5.3.4. Asia Pacific
5.3.5. Middle East and Africa (MEA)
5.4. Absolute $ Opportunity Assessment by Region
5.5. Market Attractiveness/Growth Potential Analysis by Region
5.6. Global Human Rabies Vaccine Demand Share Forecast, 2019-2026
6. North America Human Rabies Vaccine Market Analysis and Forecast
6.1. Introduction
6.1.1. Basis Point Share (BPS) Analysis by Country
6.1.2. Y-o-Y Growth Projections by Country
6.2. North America Human Rabies Vaccine Market Size and Volume Forecast by Country
6.2.1. U.S.
6.2.2. Canada
6.3. Absolute $ Opportunity Assessment by Country
6.4. Market Attractiveness/Growth Potential Analysis
6.4.1. By Country
6.4.2. By Product Type
6.4.3. By Application
6.5. North America Human Rabies Vaccine Demand Share Forecast, 2019-2026
7. Latin America Human Rabies Vaccine Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.1.3. Latin America Average Pricing Analysis
7.2. Latin America Human Rabies Vaccine Market Size and Volume Forecast by Country
7.2.1. Brazil
7.2.2. Mexico
7.2.3. Rest of Latin America
7.3. Absolute $ Opportunity Assessment by Country
7.4. Market Attractiveness/Growth Potential Analysis
7.4.1. By Country
7.4.2. By Product Type
7.4.3. By Application
7.5. Latin America Human Rabies Vaccine Demand Share Forecast, 2019-2026
8. Europe Human Rabies Vaccine Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Europe Average Pricing Analysis
8.2. Europe Human Rabies Vaccine Market Size and Volume Forecast by Country
8.2.1. Germany
8.2.2. France
8.2.3. Italy
8.2.4. U.K.
8.2.5. Spain
8.2.6. Russia
8.2.7. Rest of Europe
8.3. Absolute $ Opportunity Assessment by Country
8.4. Market Attractiveness/Growth Potential Analysis
8.4.1. By Country
8.4.2. By Product Type
8.4.3. By Application
8.5. Europe Human Rabies Vaccine Demand Share Forecast, 2019-2026
9. Asia Pacific Human Rabies Vaccine Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Asia Pacific Average Pricing Analysis
9.2. Asia Pacific Human Rabies Vaccine Market Size and Volume Forecast by Country
9.2.1. China
9.2.2. Japan
9.2.3. South Korea
9.2.4. India
9.2.5. Australia
9.2.6. Rest of Asia Pacific (APAC)
9.3. Absolute $ Opportunity Assessment by Country
9.4. Market Attractiveness/Growth Potential Analysis
9.4.1. By Country
9.4.2. By Product Type
9.4.3. By Application
9.5. Asia Pacific Human Rabies Vaccine Demand Share Forecast, 2019-2026
10. Middle East & Africa Human Rabies Vaccine Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Middle East & Africa Average Pricing Analysis
10.2. Middle East & Africa Human Rabies Vaccine Market Size and Volume Forecast by Country
10.2.1. Saudi Arabia
10.2.2. South Africa
10.2.3. UAE
10.2.4. Rest of Middle East & Africa (MEA)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Market Attractiveness/Growth Potential Analysis
10.4.1. By Country
10.4.2. By Product Type
10.4.3. By Application
10.5. Middle East & Africa Human Rabies Vaccine Demand Share Forecast, 2019-2026
11. Competition Landscape
11.1. Global Human Rabies Vaccine Market: Market Share Analysis
11.2. Human Rabies Vaccine Distributors and Customers
11.3. Human Rabies Vaccine Market: Competitive Dashboard
11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
11.4.1. Medimmune LLC. Novartis Vaccines and Diagnostics Ltd. GlaxoSmithKline Biologicals Cadila Pharmaceuticals Ltd. Merck & Co Inc. Berna Biotech Ltd.
Segments Covered in the Report
The global human rabies vaccine market has been segmented on the basis of
Products
The global human rabies vaccine market has been segmented on the basis of
Products
- Pre-Exposure Vaccination
- Post-Exposure Prophylaxis
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Medimmune LLC.
- Novartis Vaccines and Diagnostics Ltd.
- GlaxoSmithKline Biologicals
- Cadila Pharmaceuticals Ltd.
- Merck & Co Inc.
- Berna Biotech Ltd.
- Sanofi Pasteur, Inc.
- Wyeth pharmaceuticals
Key players competing in the global human rabies vaccine market are Medimmune LLC.; Novartis Vaccines and Diagnostics Ltd.; GlaxoSmithKline Biologicals; Cadila Pharmaceuticals Ltd.; Merck & Co Inc.; Berna Biotech Ltd.; Sanofi Pasteur, Inc.; and Wyeth pharmaceuticals. Many of these players have adopted business strategies such as the launch of new products, the advancement of technologies, mergers, partnerships, and production capacity expansion to increase their market position and expand their consumer base globally.
Our Clients
Related Reports
Some other reports from this category!
